News & Events
Clinical Research and Pharmaceutical Innovation Cooperation Forum: Clinical Research Spurring High-quality Development
News & Events CBIIC 2023.04.06 313

Clinical Research and Pharmaceutical Innovation Cooperation Forum was set up at the 7th China BioMed Innovation and Investment Conference on 30th March. Heads of clinical research from 10 hospitals and R&D leaders from pharmaceutical innovative enterprises engaged in enriched and in-depth discussion on the forum. The forum was chaired by Cui Yimin, chairman of PhIRDA Clinical Trial Research Specialty Committee, and director of Institute of Clinical Pharmacology, Peking University. Cui introduced the forum’s policy background.


Cui Yimin

Song Yuqin, vice president and deputy director of Lymphoma Department of Beijing Cancer Hospital, addressed a report entitled “Clinical Research Accelerates Drug Development with New Technologies and New Targets”.


Song Yuqin

Zhang Dan, foreign academician of the Russian Academy of Engineering, co-founder and chief strategic officer of ClinChoice, made a keynote speech entitled “MRCT and Globalization of Innovative Drugs”.


Zhang Dan

On behalf of Li Ning, vice president of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Tang Yu, head of Office of Clinical Trial Research Center of National Cancer Center or Cancer Hospital, Chinese Academy of Medical Sciences, addressed a keynote speech entitled “Construction and Development Prospects of the Research Hospital”.


Tang Yu

Panel 1 centered on “Patient-Focused, Improve Clinical Research Capabilities Comprehensively”, chaired by Li Shuya, director of Drug Clinical Trials Institutions, Beijing Tiantan Hospital. Panelists included Zhu Chouwen, president of Shanghai Clinical Research and Trial Center and Shanghai Tech University Research Hospital (under construction), Li Peiying, director of the Clinical Research Center, deputy director of Department of Anesthesiology of Renji Hospital, Shanghai Jiaotong University School of Medicine, and Howard Huang, CEO of Fosun Kite Biotechnology Co.,Ltd..


Panel: Li Shuya, Zhu Chouwen, Li Peiying, Howard Huang (From Left to Right)

Qin Huanlong, president of Shanghai Tenth People’s Hospital / Tenth People’s Hospital of Tongji University, addressed a keynote speech entitled “Effect and Thinking of the Construction of Clinical Science and Innovation Park in Public Hospitals”.


Qin Huanlong

Miao Liyan, executive vice president of the First Affiliated Hospital of Soochow University, and director of the Interdisciplinary Institute of Drug Research and Translation, Soochow University, addressed the last keynote speech entitled “Innovate the Cooperation Model of Medical Research Enterprises and Promote the Construction of Translational Medicine”.


Miao Liyan

Panel 2 focused on “Break Through the Key Points of Industry-University-Research-Medicine and Accelerate the Transformation of Achievements”, chaired by Qu Aidong, CSO of Shanghai Institute of Biological Products Co., Ltd.. Panelists included Liu Yanfei, deputy director of Clinical Research Unit and director of the Office of Clinical Trial Institution, Fudan University, Cao Guoying, director of the Office of Drug Clinical Trials Institutions, Huashan Hospital, Fudan University, Zhang Yiwen, deputy director of Pharmacy department, and deputy director of GCP Office, Zhejiang Provincial People’s Hospital, and Carrie Zhang, vice president and head of Data Science Center, Shanghai Henlius Biotech, Inc. They pointed out that, since there are still information barriers between hospitals and enterprises, it is critical to build a clinical research platform to remove obstacles of information, resource, and talents. To this end, government needs to give support, and hospitals need to take the initiative, promote active innovation, and create a more open environment for first-line doctors to conduct higher-quality clinical research.


Panel: Qu Aiodng, Liu Yanfei, Cao Guoying, Zhang Yiwen and Carrie Zhang (From Left to Right)

In the end, moderator Cui Yimin concluded that this opportunity of exchanges between heads of clinical institutions and innovative R&D pharmaceutical enterprises from Beijing, Shanghai and Suzhou has provided inspirations experience. It is hoped that there will be more exchange opportunities like this in the future.